$11.400
+0.350 (+3.07%)At close
KROS News
KROS Events
Keros Therapeutics to Receive $20 Million Milestone Payment
Keros Therapeutics (KROS) announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda (TAK), following the dosing of the first patient in the ELRiSE MF clinical trial. ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis and anemia on concurrent ruxolitinib therapy. Under the terms of the global license agreement with Takeda to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau, which became effective on January 16, 2025, Keros received a $200M upfront cash payment in February 2025, and is eligible to receive development, commercial and sales milestones with the potential to exceed $1.1B. Keros will also be eligible to receive tiered royalties on net sales.
Keros Therapeutics Doses First Patient in Duchenne Muscular Dystrophy Trial
Keros Therapeutics announced that the first patient was dosed in the Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy.
Keros Therapeutics Files $350M Mixed Securities Shelf
Keros Therapeutics files $350M mixed securities shelf
Keros Therapeutics Approves $5M Share Repurchase Program
Keros Therapeutics (KROS) announced that its board of directors has approved a $5M share repurchase program of the company's common stock following receipt of a $20M development milestone payment under the license agreement of elritercept with Takeda (TAK) Pharmaceuticals U.S.A., Inc., following the dosing of the first patient in the ELRiSE MDS clinical trial. This approval grants Keros' management the authority to repurchase outstanding shares of the company's common stock, from time to time, in the open market and/or by such other means in accordance with applicable state and federal securities laws.
Jasbir S. Seehra: Q1 Revenue $367,000
Reports Q1 revenue $367,000, consensus $1.69M. "Continuing to progress our pipeline remains our top priority, setting the stage for future catalysts and growth opportunities," said Jasbir S. Seehra, President and Chief Executive Officer. "In addition, we are excited that our partner, Takeda Pharmaceuticals U.S.A., Inc., plans to advance elritercept into a Phase 3 clinical trial to evaluate elritercept as a treatment of anemia in myelofibrosis, broadening the indication opportunity beyond myelodysplastic syndromes."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.